Skip to main content

Table 1 Patient characteristics at baseline.

From: Macrophage Migration Inhibitory Factor (MIF) and Thyroid Hormone Alterations in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)

Patient #

Age

Sex

Diagnosis

ANCAa

Organ involvementb

CRPc

Creatinine/eGFRd

BVAS

New/relapse

1

69

M

EPGA

MPO

Pulm, kidneys, skin, joints

61

825/6

27

Relapse

2

60

M

GPA

PR-3

Pulm, kidneys, spleen

51

56/129

25

New

3

27

F

GPA

PR-3

ENT, Pulm, eyes

20

60/104

12

Relapse

4

81

F

MPA

MPO

Pulm, kidneys, Neuro

6

460/Dialysis

34

New

5

74

F

GPA

PR-3

ENT, Pulm

4

73/68

18

New

6

69

M

GPA

PR-3

ENT, Pulm

13

112/56

15

New

7

35

M

GPA

PR-3

ENT

27

74/104

11

New

8

54

M

GPA

PR-3

ENT, joints, kidneys

5

365/11

19

Relapse

9

27

M

GPA

PR-3

ENT, kidneys

1

84/95

16

New

10

67

F

MPA

MPO

Kidneys

1

260/16

12

New

11

54

M

MPA

MPO

Skin, Pulm, kidneys

16

154/41

21

New

12

71

M

GPA

PR-3

ENT, kidneys

33

124/50

9

Relapse

13

61

M

GPA

PR-3

Joints, Pulm, kidneys

6

112/58

19

New

14

65

F

GPA

PR-3

ENT, Pulm, kidneys

40

331/12

30

New

15

72

M

MPA

MPO

Kidneys, Pulm

28

91/71

13

New

16

57

F

MPA

MPO

Kidneys

2

711/5

13

New

17

71

F

MPA

MPO

Kidneys

22

491/8

12

New

18

59

M

GPA

PR-3

ENT, eyes, Pulm

1

65/120

9

New

19

71

F

GPA

MPO

ENT

1

71/70

11

New

20

20

F

GPA

PR-3

ENT, Pulm

33

41/172

10

New

21

35

F

MPA

MPO

Joints, kidneys

1

88/63

8

New

22

59

M

GPA

PR-3

ENT, Neuro, Pulm

2

50/148

10

New

23

81

M

MPA

MPO

Kidneys, Pulm

82

170/34

18

New

24

59

M

GPA

PR-3

ENT, joints, Pulm

3

74/94

7

New

25

71

M

GPA

PR-3

ENT, joints, Pulm, skin, kidneys

14

69/98

17

New

26

64

F

GPA

MPO

Joints, Pulm, kidneys

8

141/33

18

New

27

19

F

MPA

MPO

Kidneys

1

83/77

5

Relapse

  1. Abbreviations: M, Male; F, Female; ENT, ear, nose, and throat; Pulm, pulmonary system; Neuro, neurological system.
  2. aANCA antibodies were directed against MPO or PR-3.
  3. bJoints refers to arthralgia or arthritis in the joints.
  4. cCRP reference was <1 mg/L.
  5. dCreatinine reference was <100 µmol/L for males and <90 µmol/L for females; eGFR is calculated using the MDRD formula.